BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 30738967)

  • 1. Highly conserved epitopes of DENV structural and non-structural proteins: Candidates for universal vaccine targets.
    Verma M; Bhatnagar S; Kumari K; Mittal N; Sukhralia S; Gopirajan At S; Dhanaraj PS; Lal R
    Gene; 2019 May; 695():18-25. PubMed ID: 30738967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses.
    Wollner CJ; Richner M; Hassert MA; Pinto AK; Brien JD; Richner JM
    J Virol; 2021 May; 95(12):. PubMed ID: 33762420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1.
    Messer WB; Yount BL; Royal SR; de Alwis R; Widman DG; Smith SA; Crowe JE; Pfaff JM; Kahle KM; Doranz BJ; Ibarra KD; Harris E; de Silva AM; Baric RS
    J Virol; 2016 May; 90(10):5090-5097. PubMed ID: 26962223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine.
    Galula JU; Shen WF; Chuang ST; Chang GJ; Chao DY
    J Virol; 2014 Sep; 88(18):10813-30. PubMed ID: 25008922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.
    Thomas A; Thiono DJ; Kudlacek ST; Forsberg J; Premkumar L; Tian S; Kuhlman B; de Silva AM; Metz SW
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32611757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope.
    Metz SW; Thomas A; White L; Stoops M; Corten M; Hannemann H; de Silva AM
    Virol J; 2018 Apr; 15(1):60. PubMed ID: 29609659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Universal Dengue Vaccine Elicits Neutralizing Antibodies against Strains from All Four Dengue Virus Serotypes.
    Uno N; Ross TM
    J Virol; 2021 Jan; 95(4):. PubMed ID: 33208445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by National Institutes of Health Monovalent Dengue Virus Vaccines.
    Swanstrom JA; Nivarthi UK; Patel B; Delacruz MJ; Yount B; Widman DG; Durbin AP; Whitehead SS; De Silva AM; Baric RS
    J Infect Dis; 2019 Jun; 220(2):219-227. PubMed ID: 30895307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection.
    Rivino L; Kumaran EA; Jovanovic V; Nadua K; Teo EW; Pang SW; Teo GH; Gan VC; Lye DC; Leo YS; Hanson BJ; Smith KG; Bertoletti A; Kemeny DM; MacAry PA
    J Virol; 2013 Mar; 87(5):2693-706. PubMed ID: 23255803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes.
    Andrade DV; Katzelnick LC; Widman DG; Balmaseda A; de Silva AM; Baric RS; Harris E
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoinformatics and molecular docking studies reveal potential epitope-based peptide vaccine against DENV-NS3 protein.
    Tahir RA; Wu H; Rizwan MA; Jafar TH; Saleem S; Sehgal SA
    J Theor Biol; 2018 Dec; 459():162-170. PubMed ID: 30291844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
    Ramasamy V; Arora U; Shukla R; Poddar A; Shanmugam RK; White LJ; Mattocks MM; Raut R; Perween A; Tyagi P; de Silva AM; Bhaumik SK; Kaja MK; Villinger F; Ahmed R; Johnston RE; Swaminathan S; Khanna N
    PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006191. PubMed ID: 29309412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary evaluation of DNA vaccine candidates encoding dengue-2 prM/E and NS1: their immunity and protective efficacy in mice.
    Lu H; Xu XF; Gao N; Fan DY; Wang J; An J
    Mol Immunol; 2013 Jun; 54(2):109-14. PubMed ID: 23270684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
    Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
    BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
    Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dengue Virus Serotype 1 Conformational Dynamics Confers Virus Strain-Dependent Patterns of Neutralization by Polyclonal Sera.
    VanBlargan LA; Milutinovic PS; Goo L; DeMaso CR; Durbin AP; Whitehead SS; Pierson TC; Dowd KA
    J Virol; 2021 Nov; 95(23):e0095621. PubMed ID: 34549976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes.
    Gallichotte EN; Baric TJ; Yount BL; Widman DG; Durbin A; Whitehead S; Baric RS; de Silva AM
    PLoS Pathog; 2018 Feb; 14(2):e1006934. PubMed ID: 29481552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondary infection.
    Weiskopf D; Angelo MA; Sidney J; Peters B; Shresta S; Sette A
    J Virol; 2014 Oct; 88(19):11383-94. PubMed ID: 25056881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine.
    Tsai WY; Chen HL; Tsai JJ; Dejnirattisai W; Jumnainsong A; Mongkolsapaya J; Screaton G; Crowe JE; Wang WK
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30185598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dengue Vaccines: The Promise and Pitfalls of Antibody-Mediated Protection.
    Martinez DR; Metz SW; Baric RS
    Cell Host Microbe; 2021 Jan; 29(1):13-22. PubMed ID: 33444553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.